Aflo Analytics raises £1.2M pre-seed to bring asthma-monitoring platform to market
What's the deal? Respiratory AnalyticsDealroom has a profile for this one. Try Dealroom →, the company behind the aflo®Dealroom has a profile for this one. Try Dealroom → respiratory platform, has raised £1.2 million in a pre-seed round led by Angel AcademeDealroom has a profile for this one. Try Dealroom →. SyndicateRoomDealroom has a profile for this one. Try Dealroom →, QUBISDealroom has a profile for this one. Try Dealroom →, and The Amp SyndicateDealroom has a profile for this one. Try Dealroom → also backed the round, alongside angel investors from the UK, US, and Europe.
What's the company building? aflo® gives clinicians objective data on how asthma patients actually use their inhalers. It measures inhaler technique and adherence, helping doctors understand why a patient's asthma remains uncontrolled and tailor treatment accordingly.
Where the money goes: The round combines equity investment with non-dilutive grant funding. The company will use it to pursue FDA clearance, run further clinical studies, expand its team, generate health-economic evidence, and enter its first commercial asthma markets.
Why now? The raise follows a run of clinical milestones. A UK randomised controlled trial in adults and children with uncontrolled asthma showed improvements in inhaler technique, asthma control, and quality of life, plus reductions in reliever medication and healthcare use.
In July, the company completed its first US paediatric study with Boston Children's HospitalDealroom has a profile for this one. Try Dealroom →, led by Professor Wanda Phipatanakul, in children and young people with severe asthma.
What they're saying: "Closing this investment round is an important milestone," said chief executive officer and co-founder Dr Susan Kelly. "The next phase is about growing our team, regulatory clearances, further clinical validation and taking the technology into its first markets."
The signal: At £1.2 million, the round sits in the upper range for pre-seed deals, reflecting investor appetite for healthtech with clinical evidence already behind it. For aflo®, the challenge now shifts from proving the science to clearing regulators and winning commercial markets.
Read more: syncni.com
Image credit: Generated with Gemini
